Howard Parnes

Howard Parnes

UNVERIFIED PROFILE

Are you Howard Parnes?   Register this Author

Register author
Howard Parnes

Howard Parnes

Publications by authors named "Howard Parnes"

Are you Howard Parnes?   Register this Author

100Publications

2610Reads

23Profile Views

Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Cancer 2019 Sep 8;125(17):2965-2974. Epub 2019 May 8.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690759PMC
September 2019

Long-Term Effects of Finasteride on Prostate Cancer Mortality.

N Engl J Med 2019 01;380(4):393-394

CHRISTUS Santa Rosa Hospital Medical Center, San Antonio, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1809961DOI Listing
January 2019

Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.

J Urol 2017 03 6;197(3 Pt 1):640-646. Epub 2016 Sep 6.

Department of Urology, University of Rochester (TPF), Rochester, New York; Department of Urology, University of Michigan (AKG), Ann Arbor, Michigan; Urologic Oncology Branch (TPF, AKG, AK, MMa, MK, AM, HH, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Surgical Pathology (MMe), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Molecular Imaging Program (PLC, BT), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Interventional Oncology (BW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Cancer Prevention (HLP), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Urology, University of Maryland, Baltimore, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2016.08.109DOI Listing
March 2017

Commentary: Prostate cancer screening-A long run for a short slide.

Authors:
Howard L Parnes

Semin Oncol 2017 02 20;44(1):57-59. Epub 2017 Feb 20.

Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2017.02.011DOI Listing
February 2017

Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.

Oncotarget 2016 10;7(43):70794-70802

Moffitt Cancer Center & Research Institute, Inc., Biostatistics and Bioinformatics, Tampa, FL 33612-9497, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.12222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340117PMC
October 2016

Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions.

J Natl Cancer Inst 2016 09 29;108(9). Epub 2016 Apr 29.

Urologic Oncology Branch (MMS, AKG, RR, SRB, BJW, PAP), Molecular Imaging Program (BT, PLC), Division of Cancer Prevention (HLP), Laboratory of Pathology (MJM), and Center for Interventional Oncology, Department of Radiology and Imaging Sciences (BJW, PAP), National Cancer Institute, National Institutes of Health, Bethesda, MD; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, MD (RMS); Department of Surgery, Division of Urology, University of Maryland, Baltimore MD (MMS); Departments of Urology and Radiology, University of Alabama at Birmingham, Birmingham, AL (SRB)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059120PMC
September 2016

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

Am J Clin Exp Urol 2016 20;4(2):17-27. Epub 2016 Sep 20.

Department of Medicine, University of Wisconsin School of Medicine and Public HealthMadison, WI, USA; University of Wisconsin Carbone Cancer CenterMadison, WI, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069272PMC
September 2016

Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.

Eur J Cancer Prev 2016 07;25(4):312-20

aUniversity of Wisconsin Carbone Cancer Center, Madison, Wisconsin bUrology San Antonio Research, San Antonio, Texas cUniversity of Rochester Medical Center, Rochester, New York dDivision of Cancer Prevention, National Institutes of Health, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CEJ.0000000000000189DOI Listing
July 2016

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.

Cancer Epidemiol Biomarkers Prev 2016 Mar 29;25(3):463-9. Epub 2015 Dec 29.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779655PMC
March 2016

Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

Cancer Epidemiol Biomarkers Prev 2015 Oct 12;24(10):1507-15. Epub 2015 Aug 12.

Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592455PMC
October 2015

Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.

Cancer Prev Res (Phila) 2015 Jul 29;8(7):590-6. Epub 2015 Apr 29.

Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland. James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-14-0398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491033PMC
July 2015

Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance.

Urol Oncol 2015 May 6;33(5):202.e1-202.e7. Epub 2015 Mar 6.

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.01.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663486PMC
May 2015

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.

J Oncol Pharm Pract 2015 Apr 17;21(2):128-31. Epub 2014 Mar 17.

Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155214528552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4261043PMC
April 2015

Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

JAMA Dermatol 2015 Feb;151(2):170-7

Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland4section editor, JAMA Dermatology.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2014.2734DOI Listing
February 2015

Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

JAMA 2015 Jan;313(4):390-7

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland6Center for Interventional Oncology, Department of Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, National Institutes.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2014.17942DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4572575PMC
January 2015

Phase III prostate cancer chemoprevention trials.

Recent Results Cancer Res 2014 ;202:73-7

Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-45195-9_9DOI Listing
May 2014

Prostate cancer prevention: agent development strategies.

Recent Results Cancer Res 2014 ;202:121-31

Division of Cancer Prevention, 9609 Medical Center Drive, National Cancer Institute, Bethesda, MD, 20892-9783, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-642-45195-9_15
Publisher Site
http://dx.doi.org/10.1007/978-3-642-45195-9_15DOI Listing
May 2014

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Cancer Epidemiol Biomarkers Prev 2014 May 18;23(5):847-56. Epub 2014 Apr 18.

Authors' Affiliations: Departments of Pathology and Immunology; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins School of Medicine; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; Division of Cancer Prevention, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland; University of Colorado School of Medicine, Aurora, Colorado; Department of Urology, University of Texas Health Sciences Center San Antonio, San Antonio; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas; SWOG Statistical Center; Cancer Prevention Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Moores Cancer Center, University of California San Diego, La Jolla, California; and Division of Public Health Sciences and The Alvin J. Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-13-1126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012292PMC
May 2014

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

J Natl Cancer Inst 2014 Mar 22;106(3):djt456. Epub 2014 Feb 22.

Affiliations of authors: Cancer Prevention Program (ARK) and SWOG Statistical Center (AKD, CMT, PJG), Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Epidemiology (ARK, GEG) and Department of Environmental Health (GEG), University of Washington, Seattle, WA; University of Missouri, Research Reactor Center, Columbia, MO (JSM); Harry S. Truman Memorial Veterans Hospital, Columbia, MO (JSM); Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX (IMT); Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA (FLM); Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (LMM, HLP); Moores Cancer Center, University of California San Diego, San Diego, CA (SML); Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH (EAK).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975165PMC
March 2014

Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.

BJU Int 2014 Feb 21;113(2):254-9. Epub 2013 Nov 21.

Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.12368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873374PMC
February 2014

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

J Natl Cancer Inst 2013 Aug 10;105(15):1132-41. Epub 2013 Jul 10.

Department of Internal Medicine, Division of Cancer Prevention and Control, The Ohio State University College of Medicine, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735464PMC
August 2013

Long-term survival of participants in the prostate cancer prevention trial.

N Engl J Med 2013 Aug;369(7):603-10

University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1215932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141537PMC
August 2013

Prostate cancer prevention: strategies for agent development.

Curr Opin Oncol 2013 May;25(3):242-51

Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00001622-900000000-996
Publisher Site
http://dx.doi.org/10.1097/CCO.0b013e32835fc8d4DOI Listing
May 2013

Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.

Cancer 2013 Feb 14;119(3):593-601. Epub 2012 Aug 14.

Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27774DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502695PMC
February 2013

Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Cancer Epidemiol 2012 Dec 19;36(6):e401-6. Epub 2012 Sep 19.

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2012.08.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582194PMC
December 2012

Active surveillance for prostate cancer: past, present and future.

Curr Opin Oncol 2012 May;24(3):243-50

Urologic Oncology Branch, Center for Cancer Research, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e3283527f99DOI Listing
May 2012

Prostate cancer prevention: do the 5-ARIs make the grade?

Authors:
Howard L Parnes

Am J Bioeth 2011 Dec;11(12):30-1

National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.1080/15265161.2011.626
Publisher Site
http://dx.doi.org/10.1080/15265161.2011.626666DOI Listing
December 2011

Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial.

Biostatistics 2010 Jul 19;11(3):413-8. Epub 2010 Feb 19.

Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892-7354, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/biostatistics/kxq004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883301PMC
July 2010

BCAN Think Tank session 3: Prevention of bladder cancer.

Urol Oncol 2010 May-Jun;28(3):338-42

Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2009.06.018DOI Listing
July 2010

Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.

Cancer Prev Res (Phila) 2010 Apr 23;3(4):478-83. Epub 2010 Mar 23.

Division of Environmental Health Sciences, Columbia University, 630 West 168th Street, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-09-0201DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853720PMC
April 2010

Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Cancer Prev Res (Phila) 2010 Mar 23;3(3):279-89. Epub 2010 Feb 23.

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-09-0188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846551PMC
March 2010

Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Cancer Epidemiol Biomarkers Prev 2009 Nov 3;18(11):2807-13. Epub 2009 Nov 3.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, the James Buchanan Brady Urological Institute, and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-09-0472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877916PMC
November 2009

The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.

J Urol 2008 Aug 11;180(2):544-7. Epub 2008 Jun 11.

University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2008.04.014DOI Listing
August 2008

Estimating rates of true high-grade disease in the prostate cancer prevention trial.

Cancer Prev Res (Phila) 2008 Aug 18;1(3):182-6. Epub 2008 May 18.

Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, EPN 3064, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-07-0007DOI Listing
August 2008

Does the level of prostate cancer risk affect cancer prevention with finasteride?

Urology 2008 May;71(5):854-7

Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2008.01.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692669PMC
May 2008

Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment.

Prostate 2008 Feb;68(3):281-6

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.20637DOI Listing
February 2008

Clinical safety of a viral vector based prostate cancer vaccine strategy.

J Urol 2007 Oct 16;178(4 Pt 1):1515-20. Epub 2007 Aug 16.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2007.05.117DOI Listing
October 2007

Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.

Cancer Res 2007 Oct 25;67(19):8989-93. Epub 2007 Sep 25.

Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-3171DOI Listing
October 2007

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

J Natl Cancer Inst 2007 Sep 11;99(18):1375-83. Epub 2007 Sep 11.

Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B-216, Denver, CO 80262, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djm117DOI Listing
September 2007

Finasteride decreases the risk of prostatic intraepithelial neoplasia.

J Urol 2007 Jul 11;178(1):107-9; discussion 110. Epub 2007 May 11.

Department of Urology, University of Texas Health Science Center at San Antonio and Southwest Oncology Group, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2007.03.012DOI Listing
July 2007

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

J Clin Oncol 2007 Jul;25(21):3076-81

Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.07.6836DOI Listing
July 2007

Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.

BJU Int 2007 May;99(5):1047-55

Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, Cancer Therapy and Evaluation Program, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1464-410X.2007.06763.xDOI Listing
May 2007

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.

J Urol 2007 May;177(5):1749-52

Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2007.01.071DOI Listing
May 2007

Early treatment gets the benefit.

J Clin Oncol 2006 Nov;24(32):5172-3; author reply 5173

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2006.07.9053
Publisher Site
http://dx.doi.org/10.1200/JCO.2006.07.9053DOI Listing
November 2006

Chemoprevention in prostate cancer.

Pharmacotherapy 2006 Oct;26(10):1533; author reply 1533

Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.26.10.1533DOI Listing
October 2006

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

J Natl Cancer Inst 2006 Aug;98(16):1128-33

Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/98/16/1128.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djj307
Publisher Site
http://dx.doi.org/10.1093/jnci/djj307DOI Listing
August 2006